Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15815897 | 1.00 | NR1H2 (0.41) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL30397094 | 1.00 | NR1H2 (0.41) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL1008572 | 0.89 | NR1H2 (0.43) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL30556830 | 0.89 | NR1H2 (0.40) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL205082 | 0.89 | NR1H2 (0.51) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL2708302 | 0.89 | NR1H2 (0.51) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL18829250 | 0.89 | NR1H2 (0.51) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL7815328 | 0.89 | NR1H2 (0.51) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL6126124 | 0.89 | NR1H2 (0.51) | NR1H2MMP2ANPEPNR1H3PTPN1 | |
| SCHEMBL7722277 | 0.87 | MMP2 (0.42) | NR1H2MMP2ANPEPNR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3404030-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180244684-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3154985-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2935279-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2935279-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885MMP2 3149/4885ANPEP 411/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885MMP2 3149/4885ANPEP 411/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885MMP2 3149/4885ANPEP 411/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885MMP2 3149/4885ANPEP 411/4885 |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885MMP2 2494/4885ANPEP 678/4885 |
| US-20160362416-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885MMP2 2494/4885ANPEP 678/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885MMP2 3149/4885ANPEP 411/4885 |
| US-20180244684-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885MMP2 2494/4885ANPEP 678/4885 |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885MMP2 3149/4885ANPEP 411/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885MMP2 2494/4885ANPEP 678/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885MMP2 3149/4885ANPEP 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.